Table 2.
Overview of clinicopathological factors that were assessed in the studies
| Clinicopathological factors | First author, year of publication (reference) | No. of studies | No. included in meta-analysis | |
|---|---|---|---|---|
| Assessed factors | Statistically significant finding | |||
| Grade | Avdan Aslan, 2021 [16]; Barreau, 2005 [19]; de Roos, 2006 [20]; Dinkel, 2000 [22]; Evans, 2010 [23]; Hofvind, 2011 [24]; Holmberg, 2013 [25]; Kessar, 2002 [26]; Kong, 2020 [28]; Lee, 2021 [30]; Rauch, 2016 [34]; Rominger, 2015 [35]; Szynglarewicz, 2016 [38]; Tan, 2000 [41]; Thurfjell, 2002 [43]; Zhou, 2017 [47] | 16 | 8 | 11 studies in meta-analysis |
| Presence (micro) invasive breast cancer | Bagnall, 2001 [18]; Lee, 2000 [29]; Nishimura, 2004 [33]; Stomper, 2003 [37]; Tabar, 2011 [40]; Thurfjell, 2002 [43]; Wang, 2019 [44]; Zhang, 2021 [46] | 8 | 1 | 5 studies in meta-analysis |
| (Comedo)necrosis | Avdan Aslan, 2021 [16]; Barreau, 2005 [19]; Holmberg, 2013 [25]; Lee, 2021 [30]; Rauch, 2016 [34]; Szynglarewicz, 2016 [38]; Tan, 2000 [41] | 7 | 4 | 5 studies in meta-analysis |
| Her2 overexpression | Avdan Aslan, 2021 [16]; Bae, 2013 [17]; Kim, 2015 [27]; Lee, 2021 [30]; Rominger, 2015 [35]; Zhou, 2017 [47] | 6 | 3 | 4 studies in meta-analysis |
| ER positivity | Avdan Aslan, 2021 [16]; Bae, 2013 [17]; Kim, 2015 [27]; Lee, 2021 [30]; Rominger, 2015 [35]; Zhou, 2017 [47] | 6 | 3 | 4 studies in meta-analysis |
| Recurrencea | Holmberg, 2013 [25]; Rauch, 2016 [34]; Rominger, 2015 [35]; Zhou, 2017 [47] | 4 | 1 | Groups not comparable for meta-analysis |
| Age | Holmberg, 2013 [25]; Szynglarewicz, 2016 [38]; Zhou, 2017 [47] | 3 | 0 | Groups not comparable for meta-analysis |
| Ki67/proliferation | Lee, 2021 [30]; Zhou, 2017 [47] | 2 | 0 | Groups not comparable for meta-analysis |
| Histological size | Evans, 2010 [23]; Holmberg, 2013 [25] | 2 | 1 | Groups not comparable for meta-analysis |
| Neoductgenesis | Zhou, 2017 [47]; Zhou, 2014 [48] | 2 | 1 | Groups not comparable for meta-analysis |
| Calcification distribution | Hofvind, 2011 [24]; Szynglarewicz, 2016 [38] | 2 | 1 | Groups not comparable for meta-analysis |
| Margin status | de Roos, 2004 [21] | 1 | 1 | Meta-analysis N/A |
| Comedocarcinoma | Barreau, 2005 [19] | 1 | 1 | Meta-analysis N/A |
| Multicentricity | Rauch, 2016 [34] | 1 | 0 | Meta-analysis N/A |
| Tenascin-C | Zhou, 2017 [47] | 1 | 1 | Meta-analysis N/A |
| Oncotype DX score | Woodard, 2019 [45] | 1 | 1 | Meta-analysis N/A |
| Progression to invasive diseasea | Lilleborge, 2021 [31] | 1 | 1 | Meta-analysis N/A |
aPrognostic outcomes